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The Space Station Freedom (SSF) Health Maintenance Facility (HMF) will provide
medical care for crew members for up to 10 days. An integral part of the required medical care
consists of providing intravenous infusion of fluids, electrolyte solutions, and nutrients to sustain
an ill or injured crew member. In terrestrial health care facilities, intravenous solutions are
normally stored in large quantities. However, due to the station's weight and volume constraints,
an adequate supply of the required solutions cannot be carded onboard SSF. By formulating
medical fluids onboard from concentrates and station water as needed, the Fluid Therapy System
(FTS) eliminates weight and volume concerns regarding intravenous fluids. The first full-system
demonstration of FTS in continuous microgravity will be conducted in Spacelab-Japan (SL-J).
The FTS evaluation consists of two functional objectives and an in-flight demonstration
of intravenous administration of fluids. The first is to make and store sterile water and IV
solutions onboard the spacecraft. If intravenous fluids are to be produced in SSF, successful
sterilization of water and reconstituting of IV solutions must be achieved (Figure 1). The second
objective is to repeat the verification of the FTS infusion pump, which had been performed in
Spacelab Life Sciences - 1 (SLS-1). During SLS-1, the FTS IV pump was operated in continu-
ous microgravity for the fwst time. The pump functioned successfully, and valuable knowledge
on its performance in continuous microgravity was obtained. Finally, the technique of starting an
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IV in microgravity will be demonstrated. The IV technique requires modifications in
microgravity, such as use of restraints for equipment and crew members involved.
Hardware for use in the experiment was developed in conjunction with manufacturers in
the medical devices field and other fields. Modified available terrestrial hardware was used
whenever possible. There are nine major components in the FTS experiment: Source Water
Container (SWC), Sterile Water for Injection Assembly (SWI), Intravenous Reconstituting
Device (IRD), Large Volume Parenteral Bags (LVP), Intravenous Fluid Infusion Pump (IV
Pump), Payload and General Support Computer (PGSC), Fluid Administration Set (FAS),
Sample Containment Device (SCD), and Flight Infusion System Test (FIST) equipment. Follow-
ing is a detailed description of each component and its role in FTS.
The SWC is a steel tank containing pressurized water for use throughout the experiment.
i Tap water will be used for the experiment. Water from the SWC passes to the SWI (Figure 3),
: L
_ which is a cartridge designed to purify water to USP XXI specifications. Purification of the
i water will be accomplished by fhst passing it across a bed of activated carbon, followed by a bed
of 50:50 activated carbon and deionizing resin, then several beds of 100% deionizing resin, and
finally through an ultrafilter. This process is intended to remove organic and halogenated
contaminants and contaminants larger than 10,000 molecular weight. In addition, the fluid will
then pass through a sterilizing microfilter to remove particles larger than 0.22 micron in size. A
conductivity indicator is used to indicate when the desired purity level has been reached (Figure
3).
1
25O
After water sterilization has been completed, water is stored in a polyvinyl chloride
(PVC) LVP bag. If intravenous fluids arc to be formulated, the IRD is used. The IRD is a
flow-through pouch containing the constituents (liquid concentrates) of the solution which are to
be mixed with the sterile water to reconstitute single units of intravenous fluids. Quick-
disconnect fittings and drippless valves allow for easy removal and change of the IRDs and
LVPs with fresh supplies.
The pump used in the verification phase is a modified commercially available and
widely-used IV pump. It has two pumping channels which allow for the simultaneous infusion
of two separate solutions at different rates. This feattLre also provides redundancy in the event
either pump channel fails. The IV pump will deliver fluid solutions via the FAS (made of PVC
connecting tubing) to the SCD, which contains a series of ten bags that will be used to hold the
samples. The PGSC, a portable personal computer, will control the operation of the IV pump
during this part of the experiment. In the FIST phase of the experiment, a crew member will
demonstrate the technique of initiating an intravenous infusion on a manikin arm (Figure 2).
Different component configurations will be used for each portion of the experiment. In
the sterile water for injection portion, the FTS will be configured only with the following equi-
pment: SWC, SWI, and LVP (Figure 1). Water will be dispensed from the SWC and will pass
through the SWI for purification. Sterile water will then pass into a LVP bag until the bag fills.
A total of 9 liters of sterile water will be produced throughout the experiment.
Of the 9 liters formed, 5 liters will be used to reconstitute the intravenous solutions. For
this part, the IRD will be placed between the SWI and the LVP bag (Figure 4). For the
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Spacelab-Jmission, solutions of sodium chloride (0.9%) and dextrose (5.0%) will be
reconstituted. The volume of fluid in the LVP is controlled by the use of a volumetric assurance
enclosure over the LVP bag. Production of sterile water and solutions will be performed
concurrently.
The next step in the experiment is the verification of the IV pump (Figure 2). Two bags,
one Containing sodium chloride solution and one containing dextrose solution, will be attached to
the IV pump using the FAS. Since IV pump operation is controlled by the PGSC, the crew
member may continue to monitor the filling of the LVP bags in the sterilization and reconstitu-
tion part of the experiment, while the computer commands the IV pump to perform the verifica-
tion taSks. The solutions will be automatically pumped into the SCD. The crew member will
interact with the IV pump at 20-minute intervals, but no data will be lost if the crew member is
delayed, because the PGSC controls start, stop, and data collection functions.
The final step in the experiment is the demonstration of intravenous infusion in continu-
ous microgravity (Figure 2). A manikin arm designed for practicing the initiation of an IV
solution will be used, along with the required supplies. The manikin arm is equipped with
venous channels to simulate a patient arm. The IV pump will operate at several infusion rates,
and intentional failures will be produced to determine effective methods for coping with the
failures.
Only one crew member will be required to perform all of the tasks previously descn'oed.
The experiment will be performed once during the mission. Shortly before initiating the in-flight
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experiment,thecrew member will notify the ground team so that a ground control experiment
may be performed simultaneously.
Post-flight, the samples will be collected at the landing site and immediately returned to
Johnson Space Center for analysis. The Johnson Space Center Biomedical Operations and
Research Branch will perform the necessary analyses and tests on the flight and ground control
samples to determine if the sterile water and IV solution production parts of the experiment were
successful.
In conclusion, this experiment will determine if intravenous solutions can be successfully
produced by mixing concentrates and water sterilized onboard a spacecraft. The experiment will
also demonstrate the performance of the IV pump in continuous microgravity, and finally, the
technique of starting an IV in microgravity will be demonstrated.
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